CD235a
GYPAproteinCD235a on erythrocyte-derived microparticles signals platelet activation and thrombus propagation during coronary occlusion.
Pathway placement
Cascade stepPlatelet adhesion & activation
Confidencemedium
RationaleErythrocyte microparticles mark platelet adhesion and ongoing thrombotic activity.
Also acts inCoagulation / thrombus
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000170180
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I37
C — confounder / Type-II63
A — assay feasibility68
E — evidence strength24
T1DI (composite)6
Specificity differential (R−C)-25.6
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Human genetic evidence
0.001
Open Targets association (NSTEMI)
Literature evidence(1)
- Growing thrombi release increased levels of CD235a(+) microparticles and decreased levels of activated platelet-derived microparticles. Validation in ST-elevation myocardial infarction patients.Journal of thrombosis and haemostasis : JTH · 2015 · PMID 26239059 · doi